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Abstract 
Background: Long non-coding RNAs (lncRNAs) have been shown to have functional roles in cancer 
biology and are dys-regulated in many tumors. Colon Cancer Associated Transcript -1 (CCAT1) is 
a lncRNA, previously shown to be significantly up-regulated in colon cancer. The aim of this study 
is to determine expression levels of CCAT1 in gastric carcinoma (GC).  
Methods: Tissue samples were obtained from patients undergoing resection for gastric carcinoma 
(n=19). For each patient, tumor tissue and normal appearing gastric mucosa were taken. Normal 
gastric tissues obtained from morbidly obese patients, undergoing laparoscopic sleeve gastrectomy 
served as normal controls (n=19). A human gastric carcinoma cell line (AGS) served as positive 
control. RNA was extracted from all tissue samples and CCAT1 expression was analyzed using 
quantitative real time-PCR (qRT-PCR). 
Results: Low expression of CCAT1 was identified in normal gastric mucosa samples obtained from 
morbidly obese patients [mean Relative Quantity (RQ) = 1.95±0.4]. AGS human gastric carcinoma 
cell line showed an elevated level of CCAT1 expression (RQ=8.02). Expression levels of CCAT1 
were approximately 10.8 fold higher in GC samples than in samples taken from the negative 
control group (RQ=21.1±5 vs. RQ=1.95±0.4, respectively, p<0.001). Interestingly, CCAT1 ex-
pression was significantly overexpressed in adjacent normal tissues when compared to the nega-
tive control group (RQ = 15.25±2 vs. RQ=1.95±0.4, respectively, p<0.001). Tissues obtained from 
recurrent GC cases showed the highest expression levels (RQ = 88.8±31; p<0.001). Expression 
levels increased with tumor stage (T4- 36.4±15, T3- 16.1±6, T2- 4.7±1), however this did not 
reach statistical significance (p=0.2). There was no difference in CCAT1 expression between in-
testinal and diffuse type GC (RQ=22.4±7 vs. 22.4±16, respectively, p=0.9). Within the normal 
gastric tissue samples, no significant difference in CCAT1 expression was observed in helicobacter 
pylori negative and positive patients (RQ= 2.4±0.9 vs. 0.93±0.2, respectively, p=0.13).  
Conclusion: CCAT1 is up-regulated in gastric cancer, and may serve as a potential bio-marker for 
early detection and surveillance. 
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Introduction 
Worldwide, gastric cancer is the fourth most 
common cancer and the second leading cause of can-
cer death. While the incidence rates have been de-
creasing in the United States, they have been steadily 
increasing in East Asia and South America [1, 2]. Ma-
jor risk factors associated with the development of 
gastric carcinoma include the presence of Helicobac-
ter Pylori infection, high salt diet, rare inherited dis-
orders, and male gender [3].  
Several genetic alterations have been identified 
as carcinogenic changes involved in the development 
of gastric carcinoma. These changes can be roughly 
divided into the activation of proto-oncogenes (c-met, 
k-sam, c-erbB2), the inactivation of tumor suppressor 
genes (p16, p53), reduction or loss in the cell adhesion 
molecule E-cadherin, telomerase reactivation, and 
microsatellite instability [4]. Nonetheless, exact 
mechanisms at the molecular level remain largely 
unknown.  
Studies focusing on finding specific molecular 
biomarkers for the detection of different cancers, have 
found recently long non-coding RNA molecules 
(lncRNA) to have functional roles in cancer biology. 
Possible mechanisms by which these lncRNAs influ-
ence carcinogensis, may be by binding to, and altering 
the function of proteins known to be involved in tu-
mor biology such as p53, or by binding to promoter 
areas of different genes and dys-regulating their ex-
pression [5-7]. Colon Cancer Associated Transcript -1 
(CCAT1) is a lncRNA, up-regulated across the ade-
noma-carcinoma sequence in colon cancer and to a 
lesser degree, up-regulated in other tumor types [8, 9]. 
CCAT1 is a 2628 nucleotide lncRNA located on 
chromosome 8q24.21 in an intergenic area described 
before as a “hot spot” harboring multiple genetic al-
ternations in both colon and prostate cancer. It is lo-
cated in the vicinity of c-MYC, a well-known tran-
scription factor [10, 11]. It was discovered using Rep-
resentational Difference Analysis (RDA), cDNA 
cloning, and rapid amplification of cDNA ends 
(RACE) [9].  
Recently, CCAT1 has been found to be highly 
expressed in gastric cancer tissues when compared 
with adjacent, normally appearing tissues. However, 
no comparison was made to normal gastric tissues 
obtained from healthy controls [12]. These data, if 
replicated by others supports a potential role for 
CCAT1 as a biomarker for gastric cancer. The aims of 
this study were: 
• To validate our preliminary (unpublished data) 
and the data, obtained by others, showing up-
regulation of CCAT1 in gastric cancer.  
• To characterize CCAT1 expression levels 
through various tumor stages. 
•  To compare CCAT1 expression to a cohort of 
patients without malignant or premalignant 
changes.  
Methods 
Patients 
This is a pathological and molecular study de-
signed and conducted on fresh-frozen human tissues. 
The study was approved by the Institutional Inde-
pendent Ethical Committee (IBE, Helsinki Committee; 
Protocol HMO-0253-10). Patients eligible for the study 
were offered participation and signed a written in-
formed consent. Eligible patients were patients with 
histological diagnosis of gastric adenocarcinoma 
scheduled to undergo gastric resection with curative 
intent. Patients with evidence of metastatic disease 
were excluded and directed towards palliative medi-
cal therapy. To be eligible for the control group, pa-
tients had to meet the national criteria for surgical 
treatment of morbid obesity and to be scheduled for 
laparoscopic sleeve gastrectomy.  
Other eligibility criteria: included: Patients above 
the age of 18 years capable of providing informed 
consent. Patients with gastric cancer who were not 
treated by chemotherapy, nor by radiation therapy 
before surgery. Patients with recurrent tumor pre-
senting at least 24 months after completion of previ-
ous therapy were allowed. 
Patients with invasive cancers other than ade-
nocarcinoma of the stomach were excluded. 
Human gastric cancer cell line (AGS, Cell line 
human, 89090402, Sigma-Aldrich) served as a positive 
control.  
Tissue procurement 
Immediately following surgical resection, the 
resected specimen was delivered fresh to the De-
partment of Pathology, where, under the supervision 
of an independent pathologist, a small portion of re-
sected tissue was snap frozen in liquid nitrogen for 
future RNA extraction. Tissues were obtained from 
the primary lesion, and from normal appearing mu-
cosa adjacent to the primary tumor site, two biopsies 
each. For the negative control group, two biopsies 
were obtained from random areas of the resected 
stomach. Final pathology reports were reviewed for 
all patients to determine either tumor stage or, for the 
negative control group, Helicobacter pylori, and gastri-
tis status. 
Total RNA isolation from tissues  
Total RNA was extracted using the miRvana® 
isolation kit (Ambion Inc., Austin, TX) in accordance 
with manufacturer instructions. Weighed tissues were 
thoroughly crushed on dry ice and disrupted with 1 
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ml/50-100 mg tissue, denaturizing lysis buffer using a 
polytron tissue homogenizer. RNA concentration was 
measured with NanoDrop® Spectrophotometer 
(ND-100, NanoDrop Technologies, Wilmington, DE) 
and stored at -80°C until further use. 
Synthesis of cDNA 
Following DNase treatment, cDNA synthesis 
was performed using random primer (Roche Diag-
nostics GmbH, Mannheim, Germany) added to 10 μl 
of RNA. After incubation, 1 μl of reverse transcriptase 
(SuperScript II Reverse Transcriptase 200 U/μl, Invi-
trogen, Carlsbad, CA) was added. The cDNA was 
stored at -20°C until used for qRT-PCR.  
Real time quantitative PCR 
Primers used were: CCAT1 (custom designed by 
Applied Biosystems Inc., Foster City, CA):  
CCAT1-Forward – 
TCACTGACAACATCGACTTTGAAG 
CCAT1-Reverse - 
GGAGAAAACGCTTAGCCATACAG 
GAPDH was used as a control gene. 
CCAT1 RNA was normalized to GAPDH-RNA 
content using ABI 7500 SDS software, v1.2.2 (Applied 
Biosystems Inc., Foster City, CA). Positive and nega-
tive controls, as well as samples with no DNA were 
included in every qRT-PC experiment. PCR reactions 
were performed using ABI qRT-PCR thermocycler 
(7500 Real Time PCR System, Applied Biosystems 
Inc., Foster City, CA). The qRT-PCR program was run 
for 40 cycles, following an initial incubation at 95°C, 
10 min. Each cycle consisted of 95°C × 15 sec. and 
60°C × 1 min. Results were analyzed as relative quan-
tity (RQ) expression of CCAT1.  
Statistical analysis 
Summary statistics were obtained using estab-
lished methods. Associations between categorical 
factors were studied with Fisher’s exact test or 
Chi-squared test, as appropriate. Continuous varia-
bles between study groups were compared using the 
T-test (two-sided). Statistical analysis was performed 
using IBM-SPSS® statistical package Version 20.0 
(SPSS Inc. Chicago, IL). A p value < 0.05 was consid-
ered significant.  
Results 
Tissues were obtained, as detailed above, from 
patients that underwent surgery for gastric cancer 
(n=19), and from patients in the negative control 
group (n=19), that underwent laparoscopic sleeve 
gastrectomy for treatment of morbid obesity. Overall, 
RNA extraction and cDNA production was successful 
in 100% (19/19) of patients with GC, and in 94% 
(18/19) of patients in the negative control group.  
The patients in the study group had a mean age 
of 64.5±3 years, and consisted of 14 males (73%), and 5 
females (27%). Twelve patients (63%) had intestinal 
type GC and seven patients (37%) had diffuse type 
GC (Table 1). Expression levels of CCAT1 were ap-
proximately 10.8 fold higher in GC samples than in 
samples taken from the negative control group 
(RQ=21.1±5 vs. RQ=1.95±0.4, respectively, p<0.001, 
Table 1). As we have observed before in colon cancer, 
CCAT1 was significantly up-regulated in normal ap-
pearing tissues adjacent to the tumor site when com-
pared to normal controls (RQ = 15.25±2 vs. 
RQ=1.95±0.4, respectively, p<0.001). Interestingly 
enough, CCAT1 expression levels in histologically 
normal appearing tissues adjacent to the tumor site 
exceeded its expression levels in the tumor itself 
(Figure 1). Samples taken from patients with recurrent 
GC (sample #343, sample #443) showed the highest 
levels of CCAT1 expression (RQ = 88.8±31). There was 
a correlation between CCAT1 expression and tumor 
penetration into the gastric wall as expressed by 
T-stage (T4- RQ=36.4±15, T3- RQ= 16.1±6, T2- 
RQ=4.7±1), however, this correlation did not reach 
statistical significance (p=0.2, Figure 2). There was no 
difference in CCAT1 expression levels between intes-
tinal and diffuse type gastric cancer (RQ=22.4±7 vs. 
22.4±16, respectively, p=0.9). No difference was found 
in CCAT1 expression levels between proximal gas-
tro-esophageal junction tumors, and distal gastric 
tumors (41±22 vs. 18±6, respectively, p=0.23).  
Table 1: Clinical data, and CCAT1 expression levels in tumor & 
adjacent normal tissue. 
N Sample 
# 
Gender Age Tumor 
AJCC 
stage 
His-
to-pathologic
al subtype 
RQ 
CCAT1 In 
Tumor 
RQ CCAT1 
In adjacent 
normal 
1 343 M 77 T4N1M0 
Recurrence 
Intestinal  57.56 N/A 
2 443 M 46 T4N1M0 
Recurrence 
Diffuse  120.21 25.28 
3 496 M 75 T3N1M1 Intestinal  2.91 5.53 
4 540 M 65 T4N3M0 Diffuse  5.63 42.11 
5 560 F 48 T4N3M0 Diffuse  1.65 12.73 
6 939 M 58 T3N2M0 Intestinal  8.97 42.47 
7 1029 M 65 T3N0M0 Intestinal  34.51 14.11 
8 1064 M 60 T2N2M0 Intestinal  10.61 39.67 
9 621 M 73 T4N0M0 Diffuse  2.7 15.7 
10 743 M 82 T4N2M0 Diffuse  23.47 23.18 
11 826 M 75 T2N0M0 Intestinal  7.17 6.52 
12 865 F 34 T2N1M0 Intestinal  5.53 0.09 
13 882 M 36 T4N3M0 Diffuse  2.08 4.49 
14 919 F 72 T3N1M0 Diffuse  4.89 8.51 
15 978 F 86 T3N2M0 Intestinal  13.78 0.89 
16 982 M 80 T3N2M0 Intestinal  4.18 6.95 
17 1026 F 81 T3N1M0 Intestinal  43.62 29.48 
18 1063 M 49 T4N1M0 Intestinal  78.01 0.63 
19 1184 M 78 T2N1M0 Intestinal  1.92 9.7 
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Patients in the negative control group (n=19) had 
an average age of 43.3±2 years, and consisted of 9 men 
(50 %) and 9 women (50%). Low CCAT1 expression 
levels were detected in this group (RQ=1.95±0.4). 
Twelve patients (66%) had histological evidence of 
gastritis, and six patients (34%) were positive for the 
presence of Helicobacter Pylori. No significant differ-
ence in CCAT1 expression was observed in helico-
bacter pylori negative, and positive patients (RQ= 
2.4±0.9 vs. 0.93±0.2, respectively, p=0.13), or in gastri-
tis negative and positive patients (RQ=2.42±0.9 vs. 
0.9±0.2, p=0.28). Table 2 summarizes clinical data, and 
CCAT1 expression levels in the negative control 
group. Figure 3 summarizes CCAT1 expression levels 
in the different study groups. 
 
 
Figure 1: CCAT1 expression levels in GC tumor samples and in adjacent 
normal samples. 
 
 
Figure 2: CCAT1expression levels according to tumor (AJCC-T) stage. 
 
 
Figure 3: CCAT1 expression levels in the different study groups. 
 
Table 2: Clinical data and CCAT1 expression levels in the nega-
tive control group. 
N Sample 
# 
Gender Age Gastritis Helicobacter pylori RQ 
CCAT1 
1 3 F 53 negative negative 1 
2 15 M 54 negative negative 2.37 
3 17 F 58 negative negative 3.85 
4 32 M 56 negative negative 1.15 
5 45 M 56 negative negative 11.16 
6 48 M 46 negative negative 0.19 
7 55 F 52 negative negative 0.75 
8 1027 F 26 positive positive 0.36 
9 1040 M 32 positive positive 1 
10 1041 F 44 positive positive 0.16 
11 1042 M 45 negative negative 0.43 
12 1045 M 46 negative negative 0.82 
13 1051 F 26 positive positive 1.4 
14 1137 F 42 negative negative 0.4 
15 1162 M 44 negative negative 5.8 
16 1166 F 45 positive positive 0.64 
17 1167 F 44 positive positive 1.87 
18 1170 M 23 negative negative 1 
 
 
Discussion  
 Gastric cancer prognosis is in close correlation 
with tumor stage at diagnosis.  
Primarily due to early detection of the disease, 
and with the aid of nationwide screening programs, 
postoperative survival rates have increased in Japan 
and Korea. In the Western world, however, more than 
80% of patients at diagnosis have an advanced gastric 
cancer with poor prognosis [13, 14]. Improvement of 
survival rates is dependent upon, earlier diagnosis, 
closer monitoring of populations at risk, and new 
therapeutic strategies. Hence, the obvious need in 
improving diagnostic sensitivity, among which with 
bio-molecular tests.  
 Over the last few decades, research has focused 
on the role of protein-coding genes in the pathogene-
sis of diseases [15]. However, in recent years, evidence 
from whole genome and transcriptome sequencing 
suggests that long noncoding RNAs (lncRNAs) which 
belong to the noncoding portions of the genome, play 
a key role in oncogenesis [16]. Accumulating reports 
of dys-regulated lncRNA expression in numerous 
cancer types imply that lncRNAs may act as potential 
onco- or tumor-suppressor RNAs [17, 18]. Thus, the 
attention of research is now shifting to one of the most 
common but least well-understood RNA species: 
lncRNAs [19].  
Most of the lncRNAs studied to date in various 
cancers are overexpressed, which indicates an onco-
gene-like role of lncRNAs in cancer biology [20]. Such 
a lncRNA is CCAT1, previously found to be signifi-
cantly overexpressed in colon cancer. In these studies, 
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CCAT1 expression in colon cancer was approximately 
235 fold higher than in normal colonic tissue. 
Up-regulation was evident in pre-malignant condi-
tions and through all disease stages, including ad-
vanced metastatic disease suggesting a role in both 
tumorigenesis and the metastatic process [8, 9]. 
CCAT1 was also up-regulated in cell lines derived 
from non-small cell lung cancer and pancreatic cancer. 
Nevertheless, exact molecular mechanisms in which 
CCAT1 is involved in carcinogenesis are yet to be 
found. A recent study by Feng et al., studying CCAT1 
expression levels in gastric cancer, found that c-MYC 
directly binds to the E-box element in the promoter 
region of CCAT1, and when ectopically expressed, 
increases promoter activity and expression of CCAT1 
in gastric cancer tissues [12]. In addition, nucleotide 
substitutions in the E-box element abrogated 
c-MYC-dependent promoter activation. Moreover, 
abnormally expressed CCAT1 promoted cell prolifer-
ation and migration. However, Feng et al. compared 
GC tissues to tumor adjacent, appearing normal tis-
sues, and not to normal healthy controls. Our study 
aimed to further characterize CCAT1 expression in 
GC, and to compare expression levels to normal 
healthy controls. 
Our results show expression levels of CCAT1 
approximately 10.8 fold higher in GC samples than in 
samples taken from healthy individuals in the nega-
tive control group (RQ=21.1±5 vs. RQ=1.95±0.4, re-
spectively, p<0.001). These results further support 
previous results by Feng et al., showing an approxi-
mate 4 fold higher expression level of CCAT1 in GC 
samples when compared to adjacent normal tissues. 
As we have seen before in colon cancer tissues, 
CCAT1 expression might be higher in the histologi-
cally normal appearing tissues around the tumor than 
within the tumor tissue itself. This observation was 
previously confirmed by in-situ hybridization in or-
der to rule out contamination by shedding of cancer 
cells.  
In our study we compared tissue samples taken 
from GC tissues not only to histologically nor-
mal-appearing tissues adjacent to the tumor site, but 
also to normal gastric tissues taken from patients with 
no evidence of GC undergoing sleeve gatsrectomy 
due to morbid obesity. Interestingly, CCAT1 expres-
sion was significantly overexpressed in tu-
mor-adjacent normal tissues when compared to 
healthy controls (RQ = 15.25±2 vs. RQ=1.95±0.4, re-
spectively, p<0.001). This might be a cause of under-
lying pre-cancerous molecular events occurring in 
adjacent normal tissue causing a potential "field ef-
fect". Another explanation might be the diffuse nature 
in which some GC spread. However in a subgroup 
analysis, no difference in expression levels was found 
between the different histo-pathological, intestinal 
and diffuse subtypes (RQ=22.4±7 vs. 22.4±16, respec-
tively, p=0.9).  
As expected, the majority of the patients in our 
study (79%) were diagnosed with GC at advanced 
tumor stage. Of note, patients treated with 
neo-adjuvant chemotherapy were excluded in order 
to eliminate potential chemotherapy effect on CCAT1 
expression. CCAT1 expression level showed a trend 
towards correlation with advancement in tumor 
(AJCC-T) stage (T4- RQ=36.4±15, T3- RQ= 16.1±6, T2- 
RQ=4.7±1, p=0.2). We also demonstrated that samples 
taken from patients with recurrent GC, showed the 
highest expression of CCAT1. Similar results were 
presented by Feng et al [12]. Despite this correlation 
between mean CCAT1 expression levels and tumor 
stage, it is important to note that ten patients in the 
GC group had a higher expression levels in adjacent 
normal tissue than in tissues taken from the tumor 
itself (table 1, figure 1). In addition to technical errors 
that might explain these results, there are several 
other potential explanations. As stated above, this 
observation might be a result of potential “field ef-
fect” in adjacent normal tissues or a consequence of 
the diffuse nature in which some GC spread. Another 
theoretical explanation is that CCAT1 expression may 
fluctuate through different stages of tumorigenesis; 
reaching its peak in early stages and subsequently 
silenced at later stages. We were not able to enroll 
patients with pre-cancerous conditions or early stage 
GC into our study, therefore no statement could be 
made regarding expression levels in early GC stages. 
We believe that CCAT1 levels indeed increase with 
the advancement in tumor stage and that a larger co-
hort would have been able to achieve statistical sig-
nificance. 
The presence of Helicobacter pylori infection is 
considered a major risk factor for the development of 
GC [21]. The association between HP and CCAT1 was 
not previously studied. We hypothesized that CCAT1 
expression would be higher in normal gastric tissues 
obtained from patients, in the control group, infected 
by Helicobacter pylori due to the inflammatory process. 
Our results showed that in fact, there is no significant 
difference in CCAT1 expression in Helicobacter pylori 
negative, and positive patients (RQ= 2.4±0.9 vs. 
0.93±0.2, respectively, p=0.13). Hypothetically, 
pre-cancerous processes related to Helicobacter pylori 
infection might have still not occurred in these pa-
tients.  
This study has several limitations. The study 
group consisted of a relatively small number of pa-
tients, most of which were in advanced stages of the 
disease. Perhaps with a larger and more diverse co-
hort, we would have been able to show a significant 
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increase in CCAT1 expression with tumor advance-
ment. Significant gender and age differences between 
the two study groups are of potential bias. Theoreti-
cally, CCAT1 up-regulation might be influenced by 
age and male gender. Including patients of older age 
and more patients of male gender in the control group 
would probably be more methodologically appropri-
ate. Another limitation might be the absence of lymph 
nodes or metastasis as part of the tissues analyzed. 
Comparison of CCAT1 expression in lymph nodes 
and histo-pathological findings should be the subject 
for future research.  
Despite its limitations, our study is the second 
study to date reporting high levels of CCAT1 expres-
sion in gastric cancer, and the only study comparing 
expression levels between GC tissues and normal, 
healthy gastric tissues taken from subjects without 
cancer. We believe that CCAT1 has the potential of 
serving as a biomarker for GC, improving diagnosis 
and surveillance, as well as a target for innovative 
molecular therapies. Future large scale studies are 
needed to examine CCAT1 expression in all stages of 
GC, and to study the exact molecular mechanism in 
which CCAT1 is involved in GC oncogenesis. 
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